Cargando…
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) in...
Autores principales: | Geertsen, P F, Gore, M E, Negrier, S, Tourani, J M, von der Maase, H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409650/ https://www.ncbi.nlm.nih.gov/pubmed/15026795 http://dx.doi.org/10.1038/sj.bjc.6601709 |
Ejemplares similares
-
Prolonged continuous infusion of low-dose rIL-2.
por: Janssen, R. A., et al.
Publicado: (1994) -
On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888) -
Continuous Intravenous Infusion
por: Farquharson, Eric L.
Publicado: (1934) -
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma
por: Donskov, F, et al.
Publicado: (2005) -
Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
por: Janssen, R. A., et al.
Publicado: (1992)